Cover Image

PD-L1 expression as a biomarker for nivolumab (NIVO) plus ipilimumab (IPI) and NIVO alone in advanced melanoma (MEL): a pooled analysis

© The Author 2016. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissionsoup.com.Background: NIVO + IPI and NIVO showed superior clinical activity vs IPI in a phase 3 trial of MEL patients...

Full description

Saved in:
Bibliographic Details
Main Authors: Long, Georgina (Author) , Hassel, Jessica C. (Author)
Format: Article (Journal)
Language:English
Published: 11 October 2016
In: Annals of oncology
Year: 2016, Volume: 27
ISSN:1569-8041
DOI:10.1093/annonc/mdw379.07
Online Access:Verlag, kostenfrei, Volltext: http://dx.doi.org/10.1093/annonc/mdw379.07
Verlag, kostenfrei, Volltext: https://academic.oup.com/annonc/article/27/suppl_6/1112PD/2799923
Get full text
Author Notes:G.V. Long, J. Larkin, P.A. Ascierto, F.S. Hodi, P. Rutkowski, V. Sileni, J. Hassel, C. Lebbe, A.C. Pavlick, J. Wagstaff, D. Schadendorf, R. Dummer, D. Hogg, J.B. a. G. Haanen, P. Corrie, C. Hoeller, C. Horak, J. Wolchok, C. Robert
Description
Summary:© The Author 2016. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissionsoup.com.Background: NIVO + IPI and NIVO showed superior clinical activity vs IPI in a phase 3 trial of MEL patients (pts), irrespective of PD-L1 tumor expression. Among pts with high PD-L1 expression (≥5%), median progression-free survival (mPFS) was similar between NIVO + IPI and NIVO, but overall response rate (ORR) was higher with NIVO + IPI. We describe PD-L1 as a biomarker for NIVO + IPI and NIVO efficacy across phase 2 (CheckMate 069) and phase 3 (CheckMate 066 and 067) trials.Methods: Treatment-naïve pts (N = 832) with MEL received NIVO 1 mg/kg + IPI 3 mg/kg Q3W × 4 or NIVO 3 mg/kg Q2W, followed by NIVO 3 mg/kg Q2W until progression or unacceptable toxicity. Tumor tissue from primary or metastatic sites,...
Item Description:Gesehen am 10.11.2017
Physical Description:Online Resource
ISSN:1569-8041
DOI:10.1093/annonc/mdw379.07

Similar Items